Last reviewed · How we verify

Creatine monohydrate — Competitive Intelligence Brief

Creatine monohydrate (Creatine monohydrate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nutritional supplement / Ergogenic aid. Area: Sports performance, Neurology, Muscle disorders.

marketed Nutritional supplement / Ergogenic aid Creatine kinase system; phosphocreatine shuttle Sports performance, Neurology, Muscle disorders Small molecule Live · refreshed every 30 min

Target snapshot

Creatine monohydrate (Creatine monohydrate) — Massachusetts General Hospital. Creatine monohydrate increases phosphocreatine stores in muscle and brain cells, enhancing ATP regeneration and energy availability during high-intensity activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Creatine monohydrate TARGET Creatine monohydrate Massachusetts General Hospital marketed Nutritional supplement / Ergogenic aid Creatine kinase system; phosphocreatine shuttle

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nutritional supplement / Ergogenic aid class)

  1. Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Creatine monohydrate — Competitive Intelligence Brief. https://druglandscape.com/ci/creatine-monohydrate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: